Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 47 Financial review 2009 In accordance with US SEC disclosure requirements, the following CNS discussion compares results for the year to 31st December 2009 CNS sales decreased 44% to 1.9 billion.
with the results for the year to 31st December 2008.
The majority of GSKs CNS franchise is impacted by generic Financial information and the discussion that follows is presented competition in the USA.
The Wellbutrin decline of 67% primarily on the basis that GSK was organised and managed in 2009. reected the sale of Wellbutrin XL in the USA to Biovail in the second quarter of 2009.
Exchange Cardiovascular and urogenital The currencies that most inuence the Groups results remain the Cardiovascular and urogenital sales increased 8% to 2.3 billion.
US dollar, the Euro and the Japanese Yen.
Continued strong growth of key products such as Arixtra, up 29% During 2009, average Sterling exchange rates were weaker against to 254 million, Avodart, up 16% to 530 million, and Lovaza, the US Dollar, the Euro and the Yen compared with 2008.
2009 up 31% to 450 million, were partly offset by generic competition year-end Sterling exchange rates were stronger against all three to Coreg.
currencies compared with those at 31st December 2008.
Metabolic Pharmaceutical turnover Metabolic sales decreased 14% to 1.2 billion.
All growth rates included in the review of turnover are at constant Sales of Avandia, down 16% to 771 million, continued to decline exchange rates CER unless otherwise stated.
Sterling growth across all regions.
Bonviva Boniva sales declined in the USA by 16% rates may be found in the tables of pharmaceutical turnover by but grew in Europe and the Rest of the World.
therapeutic areas on page 48 and by geographic region on page 49.
Oncology and emesis Pharmaceutical turnover grew 2% to 23.7 billion.
Pharmaceuticals Oncology and emesis sales increased 10% to 0.6 billion.
growth was helped by sales of pandemic products.
On a regional basis, the USA declined 13% reecting continued erosion of several Tyverb Tykerb, up 45% to 169 million, grew strongly in Europe products due to generic competition.
Strong performances were and the Rest of World following product approvals gained during delivered in Europe, up 9%, Emerging Markets, up 20% and Asia 2008.
Zofran declined 11% as a result of generic competition.
The sales contribution of Stiefel, which was Vaccines acquired on 22nd July 2009, totalled 248 million.
Vaccine sales increased 30% to 3.7 billion.
Pharmaceutical turnover by therapeutic area Pandemic vaccine sales of 883 million were recorded during the GSK turnover grew by 2% in 2009 as the impact of US generic year, most of which were delivered in the fourth quarter, as GSK competition to a range of GSKs products, lower Avandia sales and partnered with governments to respond to the H1N1 pandemic.
a declining HIV business was more than offset by strong growth of Sales of GSKs new Synorix vaccine totalled 73 million, reecting key products such as Seretide Advair, Avodart, Lovaza, Relenza and launches in several markets and the beginning of shipments to the the vaccines franchise including the H1N1 pandemic vaccine.
Brazilian Government as part of the 10-year, $1.5 billion agreement Respiratory signed in August 2009.
Other strong contributors to growth for Respiratory sales increased 5% to 7.0 billion.
the year included Boostrix, up 73% to 139 million, Cervarix, up 38% to 187 million and Rotarix, up 50% to 282 million.
Partially Seretide Advair grew 5% to 5.0 billion, with especially strong offsetting these performances, sales of Infanrix Pediarix fell 15% growth in Emerging Markets, up 21% to 276 million and to 649 million, primarily as a result of the continued impact of Japan, up 79% to 195 million.
Ventolin sales grew 26% to increased competition in the DTPa sector in the USA.
Hepatitis 477 million, driven by its performance in the USA where sales vaccines sales also fell 11% to 665 million in part due to a more than doubled to 153 million.
Veramyst sales rose 72% competitor product returning to the US market.
Anti-virals Anti-virals increased 12% to 4.2 billion.
Relenza sales were 720 million in 2009 2008 57 million reecting the successful capacity expansion to meet government orders across the world and a strong retail performance in Japan of 191 million.
Sales of Valtrex declined 8% to 1.3 billion as a result of generic competition to the product in the USA which began in November 2009.
Sales of HIV medicines totalled 1.6 billion, down 7% for the year.
Epzicom sales grew 8% to 546 million but this was more than offset by declines across the rest of the portfolio.
ViiV Healthcare, the specialist HIV company established by GSK and Pzer, was ofcially launched on 3rd November 2009.
% represents growth at actual exchange rates.
GSK Annual Report 2010 Business review P08P57 Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 49 Financial review 2009 Regional analysis Consumer Healthcare turnover The turnover reported in the table below represents sales invoiced Growth % of 2009 2008 by GSKs local entity to its customers in the local market plus total m m CER% % co-promotion income within each market.
% represents growth Biotene 26 1 100 100 at actual exchange rates.
Denture care 336 271 8 24 Including Stiefel Sensodyne franchise 457 363 13 26 USA Nutritional healthcare 18 851 796 37 Sales in the USA declined 13% to 9.2 billion, principally reecting Lucozade 376 382 3 2 continued decline of Avandia down 22%, competition to Horlicks 255 204 17 25 Infanrix Pediarix down 47%, a return to market of a competitor Ribena 160 161 4 1 to the Hepatitis franchise down 21% and generic competition to significant products such as Lamictal down 68%, Imigran down 100 4,654 3,971 718 79%, Valtrex down 9%, Requip down 78% and Coreg down 28%.
In addition, Wellbutrin XL down 82%, was sold to Biovail CER% represents growth at constant exchange rates.
These declines were partly offset by significant sales of Relenza and pandemic vaccines, a doubling of Ventolin sales, Total Consumer Healthcare sales for the year rose 7% to good growth of Lovaza up 31% and contributions from recently 4.7 billion, with growth in all regions and categories.
launched products such as Boostrix and Rotarix.
OTC medicines Europe OTC product sales grew 8% to 2.3 billion in 2009, driven by sales Sales in Europe increased 9% to 7.7 billion with continued growth of Panadol up 10% to 393 million and alli, which more than of Seretide and Relenza and particularly strong vaccines growth, doubled to 203 million, as a result of launches throughout Europe driven by pandemic vaccine, offsetting the impact of generic which began in April 2009.
Sales of nicotine replacement therapy competition to a number of products and continued price cuts products declined by 1%.
from governments across the region.
Oral healthcare Emerging Markets Sales of Oral healthcare products rose 7% to 1.5 billion.
Sensodyne Sales in Emerging Markets increased 20% to 3.0 billion with performed strongly with sales up 13% to 457 million.
Denture care strong growth across the region and all therapeutic areas, helped sales grew 8% to 336 million.
Sales of Aquafresh declined 1%, as a by the acquisitions of the UCB and BMS businesses in different reduction in the US white trays market offset growth of 5% in the US countries of the region.
Aquafresh toothpaste brands, which were helped by the launch of the new Iso-active product.
Asia Pacic Japan Sales in Asia Pacic Japan grew 16% to 2.7 billion reecting Nutritional healthcare continued Seretide Advair growth, strong Relenza sales, particularly Nutritional healthcare sales grew 3% to 0.9 billion, driven by the very to the retail market in Japan, and strong vaccines growth.
strong performance of Horlicks up 17% to 255 million partly offset by a decline in Lucozade sales down 3% to 376 million which was impacted by lower sales in the impulse market of the UK market.
GSK Annual Report 2010 50 Financial review 2009 Results before major restructuring and Operating profit total results total results Total results include restructuring costs related to the Operational Excellence programme and the acquisitions of Reliant and Stiefel.
In October 2007, GSK announced a significant new Operational Excellence restructuring programme.
A second formal plan, 2009 2008 Growth representing a significant expansion of the Operational Excellence m % m % CER% % programme, was approved by the Board and announced in Turnover 28,368 100 24,352 100 3 16 February 2009.
Cost of sales 7,380 26.0 6,415 26.3 6 15 In addition to the costs of the Operational Excellence programme, Selling, general the major restructuring column in the income statement includes and administration 9,592 33.8 7,656 31.4 6 25 restructuring costs incurred solely as a direct result of any Research and restructuring programmes that follow, and relate to, material development 4,106 14.4 3,681 15.2 1 12 acquisitions where the operations of the acquired business overlap Other operating extensively with GSKs existing operations.
income 1,135 3.9 541 2.2 The acquisition of Stiefel Laboratories, Inc. in July 2009 was the Operating profit 8,425 29.7 7,141 29.3 4 18 only acquisition that meets the criteria set out above.
This is the only acquisition in 2009 where the costs incurred as a direct result Cost of sales of a related restructuring programme has been included in the Cost of sales as a percentage of turnover reduced marginally to major restructuring column.
The restructuring costs expected to 26.0% of turnover 2008 26.3%, principally reecting the impact be incurred as a direct result of this acquisition are estimated to of generic competition to higher margin products in the USA and be approximately 205 million, of which 71 million was charged changes to the product mix, offset by benets from the restructuring in 2009.
The restructuring costs incurred as a direct result of programme and lower restructuring costs of 285 million the acquisition of Reliant Pharmaceuticals Inc. the only other 2008 639 million.
acquisition since October 2007 that meets the criteria set out above, were all charged and paid in 2008.
Selling, general and administration SG&A costs as a percentage of turnover increased by 2.4 Only the restructuring costs incurred solely as a direct result of percentage points to 33.8%.
This included full year legal charges the Operational Excellence programme and the restructuring of 591 million 2008 611 million and charges related programmes following the Reliant and Stiefel acquisitions have to the major restructuring programme of 392 million been reported in the major restructuring column in the income 2008 304 million.
Excluding legal and restructuring statement.
As set out in Note 7 to the financial statements, costs, SG&A costs were 30.3% of turnover 2008 27.7%.
Major restructuring programme, asset impairments and staff This reected investment in growth markets, the acquisition of redundancies together accounted for 574 million of the 835 Stiefel, increased pension costs, the donation of H1N1 product million restructuring costs incurred in 2009.
The remaining costs to WHO and exchange losses on inter-company transactions of 261 million in 2009 arose from miscellaneous expenditures compared with exchange gains last year, partially offset by incurred solely as a direct result of the restructuring programmes.
the benets of the current restructuring programme.
No costs arising from GSKs ongoing operating activities have been reported in the major restructuring column.
Research and development For the latest position on Results before major restructuring and R&D expenditure was 14.4% 2008 15.2% of total turnover, total results see Results before major restructuring and total results which included 167 million of intangible asset write-offs in the 2010 Financial review on page 36.
2008 85 million partially offset by lower charges relating to the major restructuring programme of 155 million GSKs operating profit, profit before taxation, taxation and profit 2008 175 million and a provision release due to reassessment for the year are discussed below in terms of both total results, of a receivable balance.
Increased investment in vaccines R&D and which include major restructuring costs, and results before late stage pharmaceutical R&D were broadly offset by savings from major restructuring.
Other operating income Other operating income was 1,135 million including gains from asset disposals of 579 million 2008 293 million primarily reecting the disposal of Wellbutrin XL and various assets to Aspen Pharmacare, royalty income of 296 million 2008 307 million, a royalty dispute settlement gain of 78 million, and a one-time accounting gain of 296 million on the creation of ViiV Healthcare, partially offset by equity investment impairments of 135 million.
Operating profit total results Total operating profit for the year was 8,425 million, an increase of 4% CER and 18% in Sterling terms, compared with 2008.
The operating profit margin increased 0.4 percentage points reecting higher other operating income and broadly at R&D expenditure, partially offset by increases in cost of sales and SG&A.
GSK Annual Report 2010 Business review P08P57 Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 51 Financial review 2009 Selling, general and administration profit before taxation total results SG&A costs as a percentage of turnover increased by 2.2 Net finance costs percentage points to 32.4%, including full year legal charges of 2009 2008 591 million.
The increase reected investment in growth markets, Finance income m m the acquisition of Stiefel, increased pension costs, the donation Interest and other finance income 67 321 of H1N1 product to WHO and exchange losses on inter-company Unwinding of discounts on assets 2 1 transactions compared with exchange gains last year, partially Fair value adjustments and hedges 1 9 offset by the benets of the current restructuring programme.
70 313 Research and development R&D expenditure was 13.9% 2008 14.4% of total turnover, Finance costs which included 167 million of intangible asset write-offs Interest costs 770 829 2008 85 million partially offset by a provision release due Unwinding of discounts on liabilities 11 16 to reassessment of a receivable balance.
Increased investment in Fair value adjustments and hedges 2 2 vaccines R&D and late-stage pharmaceutical R&D were broadly offset by savings from the restructuring programme.
783 843 Other operating income profit on disposal of interest in associate Other operating income was 1,135 million including gains profit on disposal of interest in associate was 115 million as from asset disposals of 579 million 2008 293 million 5.7 million shares from the Groups holding in Quest Diagnostics primarily reecting the disposal of Wellbutrin XL and various Inc. were sold in the first quarter of 2009. assets to Aspen Pharmacare, royalty income of 296 million 2008 307 million, a royalty dispute settlement gain of Share of after tax profits of associates and joint ventures 78 million, and a one-time accounting gain of 296 million The share of after tax profits of associates of 64 million on the creation of ViiV Healthcare, partially offset by equity 2008 48 million arises principally from the Groups holding investment impairments of 135 million.
In 2009 other operating in Quest.
income and profit on disposal of associates amounted to 1,250 million.
profit before taxation total results Taking account of net finance costs, the profit on disposal of Operating profit results before major restructuring interest in associates and the share of profits of associates, Operating profit before major restructuring for the year was total profit before taxation was 7,891 million compared 9,257 million, a 1% CER decline, but up 12% in Sterling terms, with 6,659 million in 2008, a 4% CER increase and a 19% compared with 2008.
The operating profit margin was 32.6% sterling increase.
The decline in margin was primarily due to generic competition in the USA which Operating profit results before major impacted cost of goods and increased investment to support the restructuring Groups diversication strategy which impacted SG&A, partly offset by a higher level of other operating income.
The results before major restructuring are set out below: Further information on operating profit before major restructuring 2009 2008 Growth is provided in Note 6, Segment information.
m % m % CER% % Turnover 28,368 100 24,352 100 3 16 Cost of sales 7,095 25.0 5,776 23.7 13 23 Selling, general and administration 9,200 32.4 7,352 30.2 6 25 Research and development 3,951 13.9 3,506 14.4 2 13 Other operating income 1,135 3.9 541 2.2 Operating profit 9,257 32.6 8,259 33.9 1 12 Cost of sales Cost of sales increased to 25.0% of turnover 2008 23.7%, principally reecting the impact of generic competition to higher margin products in the USA and changes to the product mix, partly offset by benets from the restructuring programme.
GSK Annual Report 2010 52 Financial review 2009 profit before taxation results before major profit for the year restructuring Growth 2009 2008 m m CER% % Net finance costs Total profit after taxation 2009 2008 Finance income m m for the year 5,669 4,712 6 20 Total profit attributable to Interest and other income 67 321 shareholders 5,531 4,602 6 20 Unwinding of discounts on assets 2 1 Basic earnings per share pence 109.1p 88.6p Fair value adjustments and hedges 1 9 Basic earnings per ADS US$ $3.40 $3.28 70 313 Results before major restructuring Finance costs profit after taxation for the year 6,283 5,551 13 Results before major restructuring Interest costs 770 829 profit attributable to shareholders 6,145 5,441 13 Unwinding of discounts on liabilities 8 11 Adjusted earnings per share pence 121.2p 104.7p 2 16 Fair value adjustments and hedges 2 2 Adjusted earnings per ADS US$ $3.78 $3.87 780 838 Weighted average number of shares millions 5,069 5,195 profit on disposal of interest in associate Diluted total earnings per share pence 108.2p 88.1p profit on disposal of interests in associates was 115 million as Diluted total earnings per ADS US$ $3.38 $3.26 5.7 million Quest shares were sold in the first quarter of 2009.
Diluted weighted average number Share of after tax profits of associates and joint ventures of shares millions 5,108 5,226 The share of after tax profits of associates of 64 million 2008 48 million arises principally from the Groups holding Total results including restructuring costs produced a basic EPS of in Quest Diagnostics Inc. 109.1p compared with 88.6p in 2008.
This was an 8% growth in CER terms and a 23% growth in sterling terms.
Excluding major profit before taxation results before major restructuring restructuring costs, EPS was 121.2p compared with 104.7p.
Taking account of net finance costs, the profit on disposal of interests in associates and the share of profits of associates, profit Dividend before tax before major restructuring was 8,726 million compared The Board declared a fourth interim dividend of 18 pence per with 7,782 million in 2008, a 1% CER decline but 12% increase share resulting in a dividend for the year of 61 pence: a four pence in sterling terms.
increase over the 57 pence per share for 2008.
Taxation 2009 2008 m m UK corporation tax 417 289 Overseas taxation 1,997 1,589 Current taxation 2,414 1,878 Deferred taxation 192 69 Taxation on total profits 2,222 1,947 The charge for taxation on total profits amounted to 2,222 million and represented an effective tax rate of 28.2% 2008 29.2%.
The charge for taxation on profit before major restructuring charges amounting to 2,443 million represents an effective tax rate of 28.0% 2008 28.7%.
The Groups balance sheet at 31st December 2009 included a tax payable liability of 1,451 million and a tax recoverable asset of 58 million.
On 19th November 2009 the IRS conceded all asserted tax deficiencies and penalties arising from its reclassication of an inter-company nancing arrangement from debt to equity resulting in no additional tax cost to GSK.
For the latest position on Taxation see Taxation in the Financial review on page 39.
GSK Annual Report 2010 Business review P08P57
